腎泌尿器外科

業績一覧

学術的業績・受賞

当科では、適正な泌尿器がん診療の発展・確立に貢献すべく積極的に学術活動を行い、国際的にも認められる業績を上げています。主な業績を紹介します(2020年12月現在)。

受賞

    1. Koga F. European Urology Reviewer of the Year 2020 from European Association of Urology. 2020
    2. Koga F. European Urology Reviewer of the Month March 2020 from European Association of Urology. 2020
    3. 古賀文隆、伊藤将也、鈴木宏明、竹村公佑、片岡 円、中西泰一、飯田典之、布施 洸、鳶巣賢一. MRI拡散係数を用いた上部尿路上皮癌の筋層浸潤/局所進行癌予測モデル.学会奨励賞、第5回日本費表記腫瘍学会.
    4. 竹村公佑. 第5回 米国癌治療学会(ASCO)/日本癌治療学会(JSCO)フェローシップ・プログラム 学会奨励賞
    5. Koga F. European Urology Reviewer of the Month October 2014 from European Association of Urology. 2014
    6. 福島啓司、古賀文隆、中西泰一、横山みなと、鳶巣賢一. 進行尿路上皮がんのバイオマーカーとしてのサルコペニアの意義. 最優秀演題、泌尿器腫瘍放射線(GUTR)研究会 2014.
    7. Koga F, Fujii Y, Ishioka J, Matsuoka Y, Numao N, Saito K, Masuda H, Kawakami S, Kihara K. Risk factors for intravesical tumor recurrence in muscle-invasive bladder cancer patients treated with selective bladder-sparing approaches. Best Poster Presentation Award. European Association of Urology 2013.
    8. Fukushima H, Saito K, Ishioka J, Matsuoka Y, Numao N, Koga F, Masuda H, Fujii Y, Sakai Y, Arisawa C, Okuno T, Yonese J, Kamata S, Nagahama K, Akira Noro, Morimoto S, Tsujii T, Kitahara S, Gotoh S, Higashi Y, Kihara K. Equivalent survival after distal ureterectomy compared to nephroureterectomy in patients with urothelial carcinoma of the distal ureter: A propensity score-matched multi-center study. Best Poster Presentation Award. European Association of Urology 2013.

原著・総説

    1. Suzuki H, Ito M, Takemura K, Kobayashi S, Kataoka M, Iida N, Sekiya K, Matsumoto T, Koga F. The controlling nutritional status (CONUT) score is a prognostic biomarker in advanced urothelial carcinoma patients treated with first-line platinum-based chemotherapy. Bladder Cancer, in press.
    2. Nakanishi Y, Ito M, Kataoka M, Ikuta S, Sakamoto K, Takemura K, Suzuki H, Tobisu KI, Koga F. Who Can Avoid Biopsy of MRI-negative Lobes Without Compromising Clinically Significant Cancer Detection in Men with Unilateral MRI-positive Lobes? Urol Int, in press.
    3. Fuse H, Ito M, Takemura K, Ikuta S, Motoi T, Okuma T, Kataoka M, Koga F. Renal Angiomyolipoma Mimicking a Well-Differentiated Retroperitoneal Liposarcoma. Case Rep Urol, in press.
    4. Fujiwara R, Takemura K, Fujiwara M, Yuasa T, Yasuoka S, Komai Y, Numao N, Yamamoto S, Yonese J. Modified Glasgow Prognostic Score as a Predictor of Prognosis in Metastatic Renal Cell Carcinoma Treated With Nivolumab. Clin Genitourin Cancer, in press.
    5. Takemura K, Sato A, Morizawa Y, Kufukihara R, Iwasa S, Satoh H. Seminal Vesicle Cysts With Upper Urinary Tract Abnormalities: A Single-center Case Series of Pediatric Zinner Syndrome. Urology, in press.
    6. Yonese I, Ito M, Takemura K, Kamai T, Koga F. A Case of Metastatic Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome-Associated Renal Cell Carcinoma Treated with a Sequence of Axitinib and Nivolumab Following Cytoreductive Nephrectomy. J Kidney Cancer VHL. 7(2):6-10, 2020.
    7. Koga F. Will chemoradiation-based bladder-sparing therapy become a standard of care for muscle-invasive bladder cancer? Transl Androl Urol. 9(3):981-982, 2020.
    8. Fukushima H, Nakanishi Y, Kataoka M, Tobisu KI, Koga F. Clinically node-positive micropapillary bladder cancer in a young female desiring to spare functional bladder and fertility. Int Cancer Conf J. 9(3):151-154, 2020.
    9. Takemura K, Yuasa T, Fujiwara R, Ito M, Suzuki H, Yonese J, Koga F. Prognostic Significance of the Controlling Nutritional Status (CONUT) Score in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab after Failure of Prior Tyrosine Kinase Inhibitors. J Urol. 204(6):1166-1172, 2020.
    10. Takemura K, Yuasa T, Inamura K, Amori G, Koga F, Board PG, Yonese J. Impact of Serum γ-Glutamyltransferase on Overall Survival in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy. Target Onol. 15(3):347-356, 2020.
    11. Izumi K, Saito K, Nakayama T, Fukuda S, Fukushima H, Uehara S, Koga F, Yonese J, Kageyama Y, Fujii Y. Contact with renal sinus is associated with poor prognosis in surgically treated pT1 clear cell renal cell carcinoma. Int J Urol. 27(8):657-662, 2020.
    12. Sakamoto K, Ito M, Ikuta S, Nakanishi Y, Kataoka M, Takemura K, Suzuki H, Tobisu KI, Koga F. Detection of Muscle-Invasive Bladder Cancer on Biparametric MRI Using Vesical Imaging-Reporting and Data System and Apparent Diffusion Coefficient Values (VI-RADS/ADC). Bladder Cancer. 6(2):161-169, 2020.
    13. Suzuki H, Ito M, Takemura K, Nakanishi Y, Kataoka M, Sakamoto K, Tobisu K, Koga F. Prognostic significance of the controlling nutritional status (CONUT) score in advanced urothelial carcinoma patients. Urol Oncol, 38(3):76e11-76e17, 2020.
    14. Koga F. Role of cytoreductive nephrectomy in metastatic renal cell carcinoma patients with tumor thrombus: does it change with development of systemic therapy? Ann Transl Med. 7(Suppl 3): S145, 2019.
    15. Takemura K, Ito M, Nakanishi Y, Kataoka M, Sakamoto K, Suzuki H, Tobisu KI, Koga F. Serum γ-Glutamyltransferase as a Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide. Anticancer Res. 39(10): 5773-5780, 2019.
    16. Koga F. What are roles of multiparametric magnetic resonance imaging prior to transurethral resection of bladder tumor? Transl Androl Urol. 8(4): 290-291, 2019.
    17. Kobayashi M, Tanaka H, Tateishi U, Numao N, Yonese J, Ito M, Koga F, Fukushima H, Uehara S, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Kihara K, Fujii Y. Impact of fluorodeoxyglucose uptake on positron emission tomography/computed tomography on chemosensitivity and survival in patients with metastatic urothelial carcinoma. Int J Urol. 26(8): 820-826, 2019.
    18. Nakanishi Y, Ito M, Fukushima H, Yokoyama M, Kataoka M, Ikuta S, Sakamoto K, Takemura K, Suzuki H, Tobisu KI, Koga F. Who Can Avoid Systematic Biopsy Without Missing Clinically Significant Prostate Cancer in Men Who Undergo Magnetic Resonance Imaging-Targeted Biopsy? Clin Genitourin Cancer. 17(3): e664-e671, 2019.
    19. Kijima T, Prince T, Neckers L, Koga F, Fujii Y. Heat shock factor 1 (HSF1)-targeted anticancer therapeutics: overview of current preclinical progress. Expert Opin Ther Targets. 23(5): 369-377, 2019.
    20. Kijima T, Tanaka H, Koga F, Masuda H, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Kihara K, Fujii Y. Selective tetramodal bladder-preservation therapy, incorporating induction chemoradiotherapy and consolidative partial cystectomy with pelvic lymph node dissection for muscle-invasive bladder cancer: oncological and functional outcomes of 107 patients. BJU Int. 124(2): 242-250, 2019.
    21. Takemura K, Motoi T, Tonooka A, Funata N, Nakanishi Y, Kataoka M, Ito M, Sakamoto K, Suzuki H, Tobisu KI, Koga F. Multifocal Synchronous Upper Urinary Tract Carcinosarcoma (Sarcomatoid Carcinoma) With Rhabdomyoblastic Differentiation. Int J Surg Pathol. 27(5): 547-552, 2019.
    22. Fukushima H, Fujii Y, Koga F. Metabolic and Molecular Basis of Sarcopenia: Implications in the Management of Urothelial Carcinoma (Review). Int J Mol Sci. 20(3): E760, 2019.
    23. Takemura K,Fukushima H, Ito M, Kataoka M, Nakanishi Y, Sakamoto K, Suzuki H, Tobisu K, Koga F. Prognostic significance of serum γ-glutamyltransferase in patients with advanced urothelial carcinoma. Urol Oncol. 37(2): 108-115, 2019.
    24. Fukushima H, Takemura K,Suzuki H, Koga F. Impact of Sarcopenia as a Prognostic Biomarker of Bladder Cancer (Review). Int J Mol Sci. 19(10): E2999, 2018.
    25. Koga F, Takemura K, Fukushima H. Biomarkers for Predicting Clinical Outcomes of Chemoradiation-Based Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer (Review). Int J Mol Sci. 19(9): E2777, 2018.
    26. Takemura K, Takazawa R, Kohno Y, Yoshida S, Kato H, Tsujii T. Vesical fungus balls (fungal bezoars) by Candida albicans mimicking urothelial carcinoma in a patient with diabetic neurogenic bladder. Urol Case Rep. 18:50-51, 2018.
    27. Kawamura N, Saito K, Inoue M, Ito M, Kijima T, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Kihara K, Fujii Y. Adherent Perinephric Fat in Asian Patients: Predictors and Impact on Perioperative Outcomes of Partial Nephrectomy. Urol Int. 101(4):437-442, 2018.
    28. Suzuki H, Takemura K, Sakamoto K, Kataoka M, Ito M, Nakanishi Y, Tobisu K, Koga F. A Case of Renal Pelvic Cancer Complicated by Horseshoe Kidney Treated with RoboSurgeon Gasless Single-Port Retroperitoneoscopic Nephroureterectomy. Case Rep Urol. 18: 323148, 2018.
    29. Tanaka H, Yoshida S, Koga F, Toda K, Yoshimura R, Nakajima Y, Sugawara E, Akashi T, Waseda Y, Inoue M, Kijima T, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Kihara K, Fujii Y. Impact of Immunohistochemistry-Based Subtypes in Muscle-Invasive Bladder Cancer on Response to Chemoradiation Therapy. Int J Radiat Oncol Biol Phys. 102(5): 1408-1416, 2018.
    30. Matsumoto A, Nakagawa T, Kanatani A, Ikeda M, Kawai T, Miyakawa J, Taguchi S, Naito A, Otsuka M, Nakanishi Y, Suzuki M, Koga F, Nagase Y, Kondo Y, Okaneya T, Tanaka Y, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y. Preoperative chronic kidney disease is predictive of oncological outcome of radical cystectomy for bladder cancer. World J Urol, 36(2): 249-56, 2018.
    31. Fukushima H, Kataoka M, Nakanishi Y, Sakamoto K, Takemura K, Suzuki H, Ito M, Tobisu K, Fujii Y, Koga F. Posttherapeutic skeletal muscle mass recovery predicts favorable prognosis in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. Urol Oncol, 36(4): 156:e9-16, 2018.
    32. Nakamura Y, Yoshida S, Tanaka H, Inoue M, Ito M, Kijima T, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Fujii Y, Kihara K. Potential Utility of Diffusion-Weighted Magnetic Resonance Imaging in Diagnosis of Residual Bladder Cancer before Second Transurethral Resection. Urol Int.98(3):298-303, 2017.
    33. Yoshida S, Ito M, Tatokoro M, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Fujii Y, Kihara K. Multitask Imaging Monitor for Surgical Navigation: Combination of Touchless Interface and Head-Mounted Display. Urol Int. 98(4):486-488, 2017.
    34. Fukushima H, Koga F. Impact of sarcopenia in the management of urological cancer patients (Review). Expert Rev Anticancer Ther, 17:455-466, 2017.
    35. Migita T, Ueda A, Oishi T, Hatano M, Seimiya H, Horiguchi S, Koga F, Shibasaki F. Epithelial-mesenchymal transition promotes SOX2 and NANOG expression in bladder cancer. Lab Invest, Lab Invest 97: 567-576, 2017.
    36. Nishizawa T, Yoshida S, Koga F, Tanaka H, Kaga M, Watanabe K, Fukushima H, Nakanishi Y, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Fujii Y, Kihara K. Standardization of the apparent diffusion coefficient value of bladder cancer across different centers: Applicability in predicting aggressive pathologic phenotypes, Clin Imaging, 44: 1: 21-126, 2017.
    37. Waseda Y, Saito K, Ishioka J, Matsuoka Y, Numao N, Fujii Y, Sakai Y, Koga F, Okuno T, Arisawa C, Kamata S, Nagahama K, Masuda H, Yonese J, Kageyama Y, Noro A, Tsujii T, Morimoto S, Gotoh S, Kihara K. Ureteral Involvement Is Associated with Poor Prognosis in Upper Urinary Tract Urothelial Carcinoma Patients Treated by Nephroureterectomy: A Multicenter Database Study, Eur Urol Focus, 2: 296-302, 2016.
    38. Koga F. Editorial Comment to Stratified analysis of 800 Asian patients after robot-assisted radical prostatectomy with a median 64 months of follow up. Int J Urol 23: 744-5, 2016.
    39. Fukushima H, Nakanishi Y, Kataoka M, Tobisu K, Koga F. Postoperative changes in skeletal muscle mass predict survival of metastatic renal cell carcinoma patients undergoing cytoreductive nephrectomy. Clin Genitourin Cancer 15: e229-38, 2017.
    40. Kataoka M, Fukushima H, Nakanishi Y, Yokoyama M, Funata N, Motoi T, Tobisu K, Koga F. Retroperitoneal Teratoma in an Adult: A Potential Pitfall in the Differential Diagnosis of Adrenal Myelolipoma. Case Rep Urol 2016:5141769, 2016.
    41. Fukushima H, Nakanishi Y, Kataoka M, Tobisu K, Koga F. Prognostic significance of sarcopenia in upper tract urothelial carcinoma patients treated with radical nephroureterectomy. Cancer Med 5: 2213-20, 2016.
    42. Fukushima H, Hozumi T, Goto T, Nihei K, Karasawa K, Nakanishi Y, Kataoka M, Tobisu K, Koga F. Prognostic significance of intensive local therapy to bone lesions in renal cell carcinoma patients with bone metastasis. Clin Exp Metastasis 33: 699-705, 2016.
    43. Fukushima H, Nakanishi Y, Kataoka M, Tobisu K, Koga F. Prognostic significance of sarcopenia in metastatic renal cell carcinoma patients. J Urol 195: 26, 2016.
    44. Ohishi T, Koga F, Migita T. Bladder Cancer Stem-Like Cells: Their Origin and Therapeutic Perspectives (Review). Int J Mol Sci 17: E43, 2015.
    45. Tanabe K, Yoshida S, Koga F, Inoue M, Kobayashi S, Ishioka J, Tamura T, Sugawara E, Saito K, Akashi T, Fujii Y, Kihara K. High Ki-67 Expression Predicts Favorable Survival in Muscle-Invasive Bladder Cancer Patients Treated With Chemoradiation-Based Bladder-Sparing Protocol. Clin Genitourinary Cancer 13: e243, 2015.
    46. Fukushima H, Koga F. Editorial Comment to Prognostic significance of visceral obesity in patients with advanced renal cell carcinoma undergoing nephrectomy. Int J Urol 22: 461, 2015.
    47. Kihara K, Koga F, Fujii Y, Masuda H, Tatokoro M, Yokoyama M, Matsuoka Y, Numao N, Ishioka J, Saito K. Gasless laparoendoscopic single-port clampless sutureless partial nephrectomy for peripheral renal tumors: Perioperative outcomes. Int J Urol 22: 349, 2015.
    48. Fukushima H, Yokoyama M, Nakanishi Y, Tobisu K, Koga F. Sarcopenia as a Prognostic Biomarker of Advanced Urothelial Carcinoma. PLoS One 10: e0115895, 2015.
    49. Tatokoro M, Koga F, Yoshida S, Kihara K. Heat shock protein 90 targeting therapy: State of the art and future perspective (Review). EXCLI J 14: 33, 2015.
    50. Inoue M, Koga F, Yoshida S, Tamura T, Fujii Y, Ito E, Kihara K. Significance of ERBB2 Overexpression in Therapeutic Resistance and Cancer-Specific Survival in Muscle-Invasive Bladder Cancer Patients Treated With Chemoradiation-Based Selective Bladder-Sparing Approach. Int J Radiat Oncol Biol Phys 90: 303, 2014.
    51. Koga F, Kobayashi S, Fujii Y, Ishioka J, Yokoyama M, Nakanishi Y, Matsuoka Y, Numao N, Saito K, Masuda H, Kihara K. Significance of Positive Urine Cytology on Progression and Cancer-Specific Mortality of Non-Muscle-Invasive Bladder Cancer. Clin Genitouri Cancer 12: e87, 2014.
    52. Kobayashi S, Koga F, Kajino K, Yoshida S, Ishii C, Tanaka H, Saito K, Masuda H, Fujii Y, Yamada T, Kihara K. Apparent diffusion coefficient value reflects invasive and proliferative potential of bladder cancer. J Mag Reson Imaging 39: 172, 2014.
    53. Yoshida S, Koga F, Masuda H, Fujii Y, Kihara K. Role of diffusion-weighted magnetic resonance imaging as an imaging biomarker of urothelial carcinoma (Review). Int J Urol 21: 1190, 2014.
    54. Yoshida S, Koga F, Kobayashi S, Tanaka H, Satoh S, Fujii Y, Kihara K. Diffusion-weighted magnetic resonance imaging in management of bladder cancer, particularly with multimodal bladder-sparing strategy (Review). World J Radiol 6: 344, 2014.
    55. Koga F, Yokoyama M, Fukushima H. Small cell carcinoma of the urinary bladder: a contemporary review with a special focus on bladder-sparing treatments (Review). Expert Rev Anticancer Ther 13: 1269, 2013.
    56. Fukushima H, Masuda H, Yokoyama M, Tatokoro M, Yoshida S, Ishioka J, Matsuoka Y, Numao N, Koga F, Saito K, Fujii Y, Kihara K. Diabetes mellitus with obesity is a predictor of recurrence in patients with non-metastatic renal cell carcinoma. Jpn J Clin Oncol 43: 740, 2013.
    57. Yoshida S, Kobayashi S, Koga F, Ishioka J, Ishii C, Tanaka H, Nakanishi Y, Matsuoka Y, Numao N, Saito K, Masuda H, Fujii Y, Kihara K. Apparent diffusion coefficient as a prognostic biomarker of upper urinary tract cancer: a preliminary report. Eur Radiol 23: 2206, 2013.

著書

    1. Koga F. Chapter VIII, 4. Tips on gasless single-port retroperitoneoscopic clampless partial nephrectomy using the 3D-head-mounted display system, in Gasless Single-Port Retroperitoneoscopic Surgery in Urology: 109-112, Igaku Tosho Shuppan, 2019.
    2. Koga F. Chapter X, 3. Gasless single-port retroperitoneoscopic radical nephroureterectomy via transumbilical approach using the 3D-head-mounted display system, in Gasless Single-Port Retroperitoneoscopic Surgery in Urology: 137-146, Igaku Tosho Shuppan, 2019.
    3. Koga F. Chapter XI, 4. Tips for gasless single-port retroperitoneoscopic radical prostatectomy using the 3D-head-mounted display system: Anatomical apical dissection, in Gasless Single-Port Retroperitoneoscopic Surgery in Urology: 161-165, Igaku Tosho Shuppan, 2019.
    4. Koga F. Chapter XIV, 2. Gasless single-port retroperitoneoscopic pelvic lymph node dissection using the 3D-head-mounted display system, in Gasless Single-Port Retroperitoneoscopic Surgery in Urology: 227-237, Igaku Tosho Shuppan, 2019.
    5. Kihara K, Fujii Y, Saito K, Koga F, Numao N, Matsuoka Y, Nagai T, Masuda H. Chapter 2. Gasless Single-Port RoboSurgeon Retroperitoneoscopic Radical Nephrectomy, in Gasless Single-Port RoboSurgeon Surgery in Urology: 23-42, Springer, 2015.
    6. Kihara K, Fujii Y, Saito K, Koga F, Numao N, Matsuoka Y, Nagai T, Masuda H. Chapter 3. Gasless Single-Port RoboSurgeon Retroperitoneoscopic Partial Nephrectomy, in Gasless Single-Port RoboSurgeon Surgery in Urology: 43-64, Springer, 2015.
    7. Kihara K, Numao N, Fujii Y, Saito K, Koga F, Matsuoka Y, Ishioka J, Masuda H. Chapter 6. Gasless Single-Port RoboSurgeon Retroperitoneoscopic Radical Prostatectomy, in Gasless Single-Port RoboSurgeon Surgery in Urology: 105-126, Springer, 2015.
    8. Kihara K, Koga F, Fujii Y, Saito K, Numao N, Matsuoka Y, Yokoyama M. Chapter 9. Gasless Single-Port RoboSurgeon Retroperitoneoscopic Pelvic Lymph Node Dissection and Inguinal Hernia Prevention, in Gasless Single-Port RoboSurgeon Surgery in Urology: 159-174, Springer, 2015.
    9. Nakanishi Y, Koga F, Fukushima H, Motoi T, Tobisu K. Chapter 9. Renal Cell Carcinoma in End-Stage Renal Disease, in Updates in Hemodialysis: 143-159, Intech, 2015.
ページの先頭へ戻る